Loading clinical trials...
Loading clinical trials...
Phase I, Double-Blinded, Placebo-Controlled Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly
Conditions
Interventions
Aluminum Phosphate
Placebo
+1 more
Locations
1
United States
Baylor College of Medicine - Molecular Virology and Microbiology
Houston, Texas, United States
Start Date
May 1, 2006
Primary Completion Date
April 1, 2008
Completion Date
April 1, 2008
Last Updated
April 12, 2013
NCT06068530
NCT05764746
NCT06549257
NCT03923725
NCT04147546
NCT03996967
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions